Carruthers S G, Pentikainen P, Hosler J P, Azarnoff D L
Clin Pharmacol Ther. 1979 Dec;26(6):682-5. doi: 10.1002/cpt1979266682.
The systemic bioavailability, elimination half-life (t1/2), and plasma concentration--response relationships of pamatolol, a relatively cardioselective beta adrenoceptor blocker, have been measured in healthy subjects. Pamatolol is rapidly and completely absorbed after oral dosing. Elimination t1/2 ranged from 2.9 to 4.6 hr after oral doses and from 2.2 to 5.6 hr after intravenous doses. There was a clear relationship between log plasma pamatolol concentration and sympathetic blockade assessed by reduction of exercise heart rate. Concentration-response curves were essentially identical after oral and intravenous doses. There is no evidence of a first-pass effect, nor is there any evidence of metabolite activity.
在健康受试者中测定了相对心脏选择性β肾上腺素受体阻滞剂帕马洛尔的全身生物利用度、消除半衰期（t1/2）以及血浆浓度-反应关系。口服给药后，帕马洛尔迅速且完全吸收。口服剂量后消除t1/2范围为2.9至4.6小时，静脉注射剂量后为2.2至5.6小时。通过运动心率降低评估的血浆帕马洛尔浓度对数与交感神经阻滞之间存在明确关系。口服和静脉注射剂量后的浓度-反应曲线基本相同。没有首过效应的证据，也没有代谢物活性的证据。
